



## I. AMENDMENT

### In the Specification.

Please amend the pages as indicated below:

Pg. 6, line 14, after "SEQ ID NO" please delete "37" and insert – 37 (position 256 corresponds to residue 21 in SEQ ID NO:39)—therefor.

Pg. 8, line 20 after "SEQ ID NO" please delete "37" and insert – 37 (position 256 corresponds to residue 80 in SEQ ID NO:39)—therefor.

Pg. 75, Line 18 after "SEQ ID NO" please delete "37" and insert – 37 (position 256 corresponds to residue 18 in SEQ ID NO:39)—therefor.

After page 140, please delete pages 141 to 150, and insert new pages 141 to 151, and renumber the following pages accordingly. The new pages 141-151 constitute the replacement sequence listing enclosed herewith. Also included with this submission is an updated replacement diskette with a complete sequence listing, including new SEQ ID NO:37-39. Applicants submit that no new matter is added with the addition of this sequence.

## II. RESPONSE TO OFFICE ACTION

### A. Status of the Claims

Claims 1-10 are presently pending.

### B. Correction of Sequence Listing

A corrected sequence listing has been enclosed. The previous sequence, SEQ ID NO:37, contained gaps. To conform with 37 C.F.R. 1.822(d)(5), SEQ ID NO:37 has been replaced with SEQ ID Nos:37-39, which comprise the amino acid sequences between each gap. To conform

BEST AVAILABLE COPY

## I. AMENDMENT

### In the Specification:

Please amend the pages as indicated below:

Pg. 6, line 14, after "at position 256" please insert --SEQ ID NO:37--

Pg. 8, line 20 after "and/or asparagine 315" please insert --SEQ ID NO:37--

Pg. 75, Line 18 after "proximity to I253" please insert --SEQ ID NO:37--

After page 140, please delete pages 141 to 147, and insert new pages 141 to 150, and renumber the following pages accordingly. The new pages 141-150 constitute the replacement sequence listing enclosed herewith. Also included with this submission is an updated replacement diskette with a complete sequence listing, including new SEQ ID NO:37. Applicants submit that no new matter is added with the addition of this sequence.

## II. RESPONSE TO OFFICE ACTION

### A. Status of the Claims

Claims 1-33 were pending at the time of the Action. Claims 11-33 have been withdrawn from consideration without prejudice or disclaimer. Claims 1-10 were rejected in this action. Therefore, claims 1-10 are presently pending.

### B. Election of Species Requirement

The Action asserts that the reply filed on December 8, 1998 was not fully responsive because it failed to specify the identities of the substituted amino acid residues as required by the